Wen-Hsuan Hou1,2,3,4, Kai-Cheng Chang5,6, Chung-Yi Li7,8, Huang-Tz Ou5. 1. Taipei Medical University, School of Gerontology Health Management and Master Program in Long-Term Care, College of Nursing, Taipei City, Taiwan. 2. Taipei Medical University, Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei City, Taiwan. 3. Taipei Medical University Hospital, Department of Physical Medicine and Rehabilitation, Taipei City, Taiwan. 4. Center of Evidence-Based Medicine, Taipei Medical University, Taipei City, Taiwan. 5. National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, Tainan City, Taiwan. 6. Chang Gung Memorial Hospital-Linkou, Department of Pharmacy, Taoyuan City, Taiwan. 7. National Cheng Kung University, Department and Institute of Public Health, College of Medicine, Tainan City, Taiwan. 8. China Medical University, Department of Public Health, College of Public Health, Taichung City, Taiwan.
Abstract
AIMS: The aim of this study was to investigate the putative link between dipeptidyl peptidase-4 inhibitor (DPP-4i) use and the risk of fracture in patients with type 2 diabetes. METHODS: This propensity-score-matched population-based cohort study was performed between 2009 and 2013 on patients with type 2 diabetes who were stable metformin users. A total of 3996 patients with type 2 diabetes used DPP-4i as a second-line antidiabetic drug. The same number of matched non-DPP-4i users were followed up until fracture occurrence, health insurance policy termination, or the end of 2013. The incidence rates of overall and cause-specific fractures were estimated based on the Poisson assumption. A multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio (HR) and 95% confidence interval (CI) to determine the association between DPP-4i use and overall and cause-specific fractures stratified by age and sex. RESULTS: Over a maximum follow-up period of 5 years, 340 DPP-4i users and 419 non-DPP-4i users were newly diagnosed with fractures, yielding incidence rates of 28.03 and 32.04 per 1000 people per year, respectively. The Cox proportional hazard model revealed that DPP-4i use significantly reduced the risk of all-cause fractures and upper extremity fractures, with adjusted HRs of 0.86 (95% CI: 0.74-0.99) and 0.75 (95% CI: 0.59-0.95), respectively. The aforementioned associations of DDP-4i use with fracture were sustained across sex and age stratifications. CONCLUSIONS: The results of this study supported the premise that DPP-4i usage is associated with a reduced risk of all-cause fractures and upper extremity fractures in patients with type 2 diabetes.
AIMS: The aim of this study was to investigate the putative link between dipeptidyl peptidase-4 inhibitor (DPP-4i) use and the risk of fracture in patients with type 2 diabetes. METHODS: This propensity-score-matched population-based cohort study was performed between 2009 and 2013 on patients with type 2 diabetes who were stable metformin users. A total of 3996 patients with type 2 diabetes used DPP-4i as a second-line antidiabetic drug. The same number of matched non-DPP-4i users were followed up until fracture occurrence, health insurance policy termination, or the end of 2013. The incidence rates of overall and cause-specific fractures were estimated based on the Poisson assumption. A multiple Cox proportional hazard model was used to estimate the covariate-adjusted hazard ratio (HR) and 95% confidence interval (CI) to determine the association between DPP-4i use and overall and cause-specific fractures stratified by age and sex. RESULTS: Over a maximum follow-up period of 5 years, 340 DPP-4i users and 419 non-DPP-4i users were newly diagnosed with fractures, yielding incidence rates of 28.03 and 32.04 per 1000 people per year, respectively. The Cox proportional hazard model revealed that DPP-4i use significantly reduced the risk of all-cause fractures and upper extremity fractures, with adjusted HRs of 0.86 (95% CI: 0.74-0.99) and 0.75 (95% CI: 0.59-0.95), respectively. The aforementioned associations of DDP-4i use with fracture were sustained across sex and age stratifications. CONCLUSIONS: The results of this study supported the premise that DPP-4i usage is associated with a reduced risk of all-cause fractures and upper extremity fractures in patients with type 2 diabetes.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins Journal: Am J Epidemiol Date: 2005-12-21 Impact factor: 4.897
Authors: R P Stolk; P L Van Daele; H A Pols; H Burger; A Hofman; J C Birkenhäger; S W Lamberts; D E Grobbee Journal: Bone Date: 1996-06 Impact factor: 4.398
Authors: Ann V Schwartz; Teresa A Hillier; Deborah E Sellmeyer; Helaine E Resnick; Edward Gregg; Kristine E Ensrud; Pamela J Schreiner; Karen L Margolis; Jane A Cauley; Michael C Nevitt; Dennis M Black; Steven R Cummings Journal: Diabetes Care Date: 2002-10 Impact factor: 19.112
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: Lancet Date: 2009-06-06 Impact factor: 79.321
Authors: J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse Journal: Bone Date: 2004-11 Impact factor: 4.398
Authors: Hsien-Yen Chang; Jonathan P Weiner; Thomas M Richards; Sara N Bleich; Jodi B Segal Journal: Am J Manag Care Date: 2012-11 Impact factor: 2.229